Cargando…

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release

BACKGROUND: Human glypican-3 (hGPC3) is a protein highly expressed in hepatocellular carcinoma (HCC) but limited in normal tissues, making it an ideal target for immunotherapy. The adoptive transfer of hGPC3-specific chimeric antigen receptor T (CAR-T) cells for HCC treatment has been conducted in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xuan, Wen, Jianyun, Yi, Honglei, Hou, Xiaorui, Yin, Yue, Ye, Guofu, Wu, Xuedong, Jiang, Xiaotao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Early diagnosis and therapeutic advances for liver cancer: from bench to bedside
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065297/ https://www.ncbi.nlm.nih.gov/pubmed/32215059 http://dx.doi.org/10.1177/1758835920910347

Ejemplares similares

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
por: Ono, Atsushi, et al.
Publicado: (2020)

The risk of liver cancer in autoimmune liver diseases
por: Lleo, Ana, et al.
Publicado: (2019)

Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
por: Xu, Weiqi, et al.
Publicado: (2019)

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019)

Single nucleotide polymorphisms in telomere length-related genes are associated with hepatocellular carcinoma risk in the Chinese Han population
por: Huang, Peng, et al.
Publicado: (2020)

Management of patients with intermediate stage hepatocellular carcinoma
por: Prince, David, et al.
Publicado: (2020)

Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization
por: Lee, Hsin-Lun, et al.
Publicado: (2019)

Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis
por: Méndez-Blanco, Carolina, et al.
Publicado: (2021)

Endovascular interventions for central vein stenosis
por: Agarwal, Anil K.
Publicado: (2015)

Current progress in ABO-incompatible kidney transplantation
por: Koo, Tai Yeon, et al.
Publicado: (2015)

RNA sequencing of the nephron transcriptome: a technical note
por: Lee, Jae Wook
Publicado: (2015)

Organ-on-a-chip and the kidney
por: Kim, Sejoong, et al.
Publicado: (2015)

Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers
por: Ayoub, Walid S., et al.
Publicado: (2019)

Neuro-tracing approach to study kidney innervation: a technical note
por: Lee, Sanghee, et al.
Publicado: (2017)

Messenger RNA vaccines against SARS-CoV-2
por: Topol, Eric J.
Publicado: (2021)

Dramatic response to local radiotherapy in a refractory metastatic mediastinal yolk sac tumor patient harboring a germline BRCA2 frameshift mutation: a case report
por: Cheng, Xi, et al.
Publicado: (2022)

Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases
por: Xuan, Liang, et al.
Publicado: (2020)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Impact of Heparanase and the Tumor Microenvironment on Cancer Metastasis and Angiogenesis: Basic Aspects and Clinical Applications
por: Vlodavsky, Israel, et al.
Publicado: (2011)

Dendritic Cell Cancer Vaccines: From the Bench to the Bedside
por: Katz, Tamar, et al.
Publicado: (2014)

Genetic Stratification in Myeloid Diseases: From Risk Assessment to Clinical Decision Support Tool
por: Ofran, Yishai
Publicado: (2014)

ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies
por: Sarig, Galit
Publicado: (2014)

Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting
por: Ringelstein-Harlev, Shimrit, et al.
Publicado: (2014)

Stem Cells for Diabetes Complications: A Future Potential Cure
por: Khamaisi, Mogher, et al.
Publicado: (2017)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
por: Graziano, Vincenzo, et al.
Publicado: (2015)

Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
por: Lipkin, Jacob S, et al.
Publicado: (2015)

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
por: Wyluda, Edward J, et al.
Publicado: (2015)

Metformin: a modulator of bevacizumab activity in cancer? A case report
por: Indraccolo, Stefano, et al.
Publicado: (2015)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy
por: Zhang, Bin, et al.
Publicado: (2016)

A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach
por: Caggiari, Laura, et al.
Publicado: (2017)

Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing
por: Yang, Shanshan, et al.
Publicado: (2017)

HIF2A germline–mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma
por: Liu, Qiuli, et al.
Publicado: (2017)

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy
por: Liu, Qiuli, et al.
Publicado: (2018)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
por: Zhu, You-cai, et al.
Publicado: (2018)

Successful treatment using apatinib in intractable brain edema: A case report and literatures review
por: Song, Yanqiu, et al.
Publicado: (2018)

Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer
por: Tsoli, Maria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rh566t009rh5ej4rgue4oobtq8